Crinetics Pharmaceuticals, INC Form 4 insider transactions

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options and sold shares on July 3, 2024, according to a recent SEC filing.

CFO Marc Wilson exercised stock options and sold shares of Crinetics Pharmaceuticals on June 28, 2024, according to a recent SEC filing.

Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, sold 956 shares of common stock on June 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on June 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Dana Pizzuti, Chief Medical and Development Officer at Crinetics Pharmaceuticals, reports the exercise of stock options and subsequent sale of shares on June 24, 2024.

Crinetics Pharmaceuticals' Chief Commercial Officer, James Hassard, exercised stock options and sold 15,000 shares of common stock on June 21, 2024, according to a Form 4 filing.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock at $43.86 per share on June 10, 2024, under a pre-arranged 10b5-1 trading plan.

Director Caren Deardorf reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals, Inc.

Director Vivaldi Coelho Rogerio reported the acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

Director Stephanie Okey received stock options and restricted stock units from Crinetics Pharmaceuticals on June 7, 2024.

Director Nichols Weston reports acquiring 3,400 shares of Crinetics Pharmaceuticals common stock and disposing of 9,400 shares, along with receiving options to purchase 12,500 shares.

Director Matthew K Fust reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

Director Camille L. Bedrosian reports acquisition of 3,400 shares of common stock and 12,500 stock options in Crinetics Pharmaceuticals.

Director Wendell Wierenga reports acquisition of 3,400 shares of common stock and 12,500 stock options in Crinetics Pharmaceuticals.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on May 28, 2024, at an average price of $47.49 per share.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on May 10, 2024, at a price of $49.43 per share.

Crinetics Pharmaceuticals' CEO Richard Struthers exercised stock options and sold shares on May 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Scott Struthers, CEO of Crinetics Pharmaceuticals, reported a gift of 350 shares of common stock in a recent SEC filing.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold 14,375 shares of common stock after exercising stock options at a lower price.

Crinetics Pharmaceuticals' CEO, Richard Scott Struthers, exercised stock options and reported changes in his beneficial ownership of company stock.

Crinetics Pharmaceuticals CEO Richard Scott Struthers exercised stock options and sold shares on April 4, 2024, according to a recent SEC Form 4 filing.

Director Stephanie Okey exercised stock options and sold shares of Crinetics Pharmaceuticals on March 28, 2024.

Crinetics Pharmaceuticals' Chief Operating Officer, Jeff E. Knight, exercised stock options and sold shares in the open market on March 22, 2024.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options and sold shares on March 20, 2024.

Director Matthew K. Fust of Crinetics Pharmaceuticals exercised stock options and sold shares on March 20, 2024, according to a Form 4 filing with the SEC.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold shares to cover tax obligations related to vesting restricted stock units.

Jeff E. Knight, COO of Crinetics Pharmaceuticals, disposed of 4,283 shares of common stock on March 18, 2024, to cover tax obligations related to vesting Restricted Stock Units.

James Hassard, Chief Commercial Officer of Crinetics Pharmaceuticals, reports disposition of shares to cover tax obligations upon vesting of Restricted Stock Units.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, reports the withholding of 3,655 common stock shares to cover tax obligations upon vesting of Restricted Stock Units.

CFO Marc Wilson reports the disposition and sale of Crinetics Pharmaceuticals (CRNX) common stock related to tax obligations and a pre-arranged trading plan.